Cassava Sciences' Shares Trade Up 20% on Updated Phase 2a Alzheimer's Data
Source: Streetwise Reports  (12/6/19)
Shares of Cassava Sciences traded 20% higher after the firm presented additional data from the Phase 2a study of its investigational drug candidate PTI-125 for Alzheimer's disease to the Clinical Trials on Alzheimer's Disease conference in San Diego, Calif. More >

Aurinia Pharma Shares Open 100% Higher on Phase 3 Lupus Data
Source: Streetwise Reports  (12/5/19)
Shares of Aurinia Pharmaceuticals traded much higher today after it reported positive results from its Phase 3 AURORA trial of Voclosporin for treatment of lupus nephritis. The company plans to submit a New Drug Application to the FDA in H1/20. More >

Immuno-Oncology Firm Expands Agreement with AbbVie
Source: Streetwise Reports  (12/4/19)
The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. More >

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously
Source: Daniel Carlson for Streetwise Reports  (12/4/19)
Daniel Carlson of Tailwinds Research initiates coverage on this clinical-stage biotech whose drug candidate works to strengthen the innate immune system. More >

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results
Source: Streetwise Reports  (12/4/19)
Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. More >

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial
Source: Streetwise Reports  (12/3/19)
Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. More >

Kodiak Shares Soar on $225 Million Royalty Deal for Retinal Drug
Source: Streetwise Reports  (12/2/19)
Shares of Kodiak Sciences traded more than 100% higher at times after the company reported that it entered into a $225 million royalty agreement for the firm's KSI-301 used in the treatment of retinal vascular diseases including age-related macular degeneration and diabetic eye diseases. More >

Coverage Initiated on Maker of Antibiotic-Free Supplement for Livestock Feed
Source: Streetwise Reports  (11/26/19)
The highlights of this investment story are outlined in a Zacks Small-Cap Research report. More >

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results
Source: Streetwise Reports  (11/26/19)
Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. More >

Regenerative Medicine Firm Advances Multifaceted Pipeline
Source: Streetwise Reports  (11/26/19)
The company continues advancing its cell therapies and medical device. More >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment
Source: Streetwise Reports  (11/25/19)
Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. More >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data
Source: Streetwise Reports  (11/22/19)
EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. More >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results
Source: Streetwise Reports  (11/21/19)
Shares of Hepion Pharmaceuticals opened higher today after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. More >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug
Source: Streetwise Reports  (11/20/19)
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. More >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data
Source: Streetwise Reports  (11/19/19)
Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. More >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data
Source: Streetwise Reports  (11/18/19)
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. More >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia
Source: Streetwise Reports  (11/15/19)
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. More >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring
Source: Streetwise Reports  (11/15/19)
Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. More >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher
Source: Streetwise Reports  (11/14/19)
Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. More >

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting
Source: Streetwise Reports  (11/13/19)
The company intends to follow up in 2020 with a Phase 2b clinical trial. More >

FDA Approval of Peanut Allergy Treatment Expected Next Year
Source: Streetwise Reports  (11/13/19)
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. More >

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast
Source: Streetwise Reports  (11/13/19)
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. More >

Seachange in Mexico on Cannabis Could Benefit This Small Cap
Source: Clive Maund for Streetwise Reports  (11/13/19)
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. More >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results
Source: Streetwise Reports  (11/8/19)
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. More >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports  (11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >